The Bcl6-SMRT/NCoR Cistrome Represses Inflammation to Attenuate Atherosclerosis
Open Access
- 4 April 2012
- journal article
- research article
- Published by Elsevier BV in Cell Metabolism
- Vol. 15 (4), 554-562
- https://doi.org/10.1016/j.cmet.2012.02.012
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Bcl-6 and NF-κB cistromes mediate opposing regulation of the innate immune responseGenes & Development, 2010
- Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell IdentitiesMolecular Cell, 2010
- Identification and Characterization of Enhancers Controlling the Inflammatory Gene Expression Program in MacrophagesImmunity, 2010
- A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivoBlood, 2009
- Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathwaysGenes & Development, 2009
- Role of platelet-derived growth factors in physiology and medicineGenes & Development, 2008
- PPARδ-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosisProceedings of the National Academy of Sciences of the United States of America, 2008
- Tendon Xanthomas in Familial Hypercholesterolemia Are Associated With Cardiovascular Risk Independently of the Low-Density Lipoprotein Receptor Gene MutationArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- BCL-6 negatively regulates macrophage proliferation by suppressing autocrine IL-6 productionBlood, 2005
- Macrophage-Targeted Overexpression of Urokinase Causes Accelerated Atherosclerosis, Coronary Artery Occlusions, and Premature DeathCirculation, 2004